QULIPTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QULIPTA (QULIPTA).
QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It competitively blocks the binding of CGRP to its receptor, thereby inhibiting CGRP-mediated vasodilation and pain transmission involved in migraine pathophysiology.
| Metabolism | Primarily metabolized by CYP3A4; minor contributions from CYP2C9, CYP2D6, and other pathways. |
| Excretion | Approximately 60% of the dose is excreted in feces (as unchanged drug and metabolites) and 40% in urine (primarily as metabolites, with <1% unchanged). |
| Half-life | Terminal elimination half-life is approximately 21 hours, supporting once-daily dosing. |
| Protein binding | Approximately 82% bound to human plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 60 L (0.86 L/kg based on 70 kg), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 76%. |
| Onset of Action | Oral: Onset of clinical effect occurs within 1–2 hours after a single dose. |
| Duration of Action | Duration of action is approximately 24 hours, allowing once-daily administration for migraine prophylaxis. |
10 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. Not recommended for GFR <30 mL/min. |
| Liver impairment | Mild (Child-Pugh A): No adjustment. Moderate (Child-Pugh B): 10 mg every other day. Severe (Child-Pugh C): Not recommended. |
| Pediatric use | Not approved for pediatric patients. |
| Geriatric use | No dose adjustment required; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QULIPTA (QULIPTA).
| Breastfeeding | There is no data on the presence of atogepant in human milk, its effects on the breastfed infant, or milk production. The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment with QULIPTA and for at least 5 days after the last dose. |
| Teratogenic Risk | QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. Based on animal studies, there is no evidence of teratogenicity; however, human data are insufficient to determine a risk. The drug should be used during pregnancy only if clearly needed. It is recommended to avoid use during the first trimester due to potential risks. In animal reproduction studies, no adverse developmental effects were observed at exposures greater than those used clinically. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to atogepant or any excipients."]
| Precautions | ["Hypersensitivity reactions (including angioedema and anaphylaxis): Discontinue if reaction occurs.","Constipation: Serious cases of constipation with severe complications reported. Monitor for severe constipation and manage appropriately.","Potential decrease in bone density: Long-term effects unknown; consider monitoring for bone loss in patients at risk.","Severe hepatic impairment: Not recommended (Child-Pugh Class C)."] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required. However, as pregnancy progresses, monitor for any adverse effects related to CGRP inhibition, such as hypertension or cardiovascular events, although no such effects have been documented. Standard pregnancy monitoring per obstetric guidelines should be followed. |
| Fertility Effects | Based on animal studies, atogepant had no adverse effects on fertility in male or female rats at exposures up to 13 times the maximum recommended human dose. There are no human data on fertility effects. |